ID
11708
Description
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo. https://clinicaltrials.gov/ct2/show/NCT00809965
Link
https://clinicaltrials.gov/ct2/show/NCT00809965
Keywords
Versions (1)
- 7/28/15 7/28/15 -
Uploaded on
July 28, 2015
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Rivaroxaban Acute Coronary Syndrome NCT00809965
Elegibility Criteria
- StudyEvent: ODM
Description
Exclusion criteria
Description
Significant renal impairment
Data type
boolean
Alias
- UMLS CUI-1
- C0035078
Description
Significant liver disease
Data type
boolean
Alias
- UMLS CUI-1
- C0085605
Description
Need for continued anticoagulant therapy
Data type
boolean
Alias
- UMLS CUI-1
- C0150457
Description
Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy
Data type
boolean
Alias
- UMLS CUI-1
- C1531588
Similar models
Elegibility Criteria
- StudyEvent: ODM